These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17699354)

  • 1. Outcome and prognosis factors in HIV-infected hemodialysis patients.
    Tourret J; Tostivint I; du Montcel ST; Bragg-Gresham J; Karie S; Vigneau C; Guiard-Schmid JB; Deray G; Bagnis CI
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1241-7. PubMed ID: 17699354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
    Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis.
    Tourret J; Tostivint I; Tézenas Du Montcel S; Karie S; Launay-Vacher V; Vigneau C; Bessette C; Deray G; Bagnis CI
    Clin Infect Dis; 2007 Sep; 45(6):779-84. PubMed ID: 17712764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.
    Choi AI; Rodriguez RA; Bacchetti P; Volberding PA; Havlir D; Bertenthal D; Bostrom A; O'Hare AM
    Clin Infect Dis; 2007 Dec; 45(12):1633-9. PubMed ID: 18190326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
    Horberg MA; Hurley LB; Klein DB; Follansbee SE; Quesenberry C; Flamm JA; Green GM; Luu T
    Arch Surg; 2006 Dec; 141(12):1238-45. PubMed ID: 17178967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort.
    de Boer-van der Kolk IM; Sprangers MA; Prins JM; Smit C; de Wolf F; Nieuwkerk PT
    Clin Infect Dis; 2010 Jan; 50(2):255-63. PubMed ID: 20014949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
    Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C;
    AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).
    Kapogiannis BG; Soe MM; Nesheim SR; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2008 May; 121(5):e1229-39. PubMed ID: 18450865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection.
    Butt AA; Fultz SL; Kwoh CK; Kelley D; Skanderson M; Justice AC
    Hepatology; 2004 Jul; 40(1):115-9. PubMed ID: 15239093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
    Sheng WH; Hung CC; Wu RJ; Wang JT; Chen PJ; Chang SC; Kao JH
    Clin Infect Dis; 2007 Feb; 44(4):584-90. PubMed ID: 17243064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low effectiveness of highly active antiretroviral therapy and high mortality in the Greenland HIV-infected population.
    Lohse N; Ladefoged K; Pedersen L; Jensen-Fangel S; Sørensen HT; Obel N
    Scand J Infect Dis; 2004; 36(10):738-42. PubMed ID: 15513400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
    Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
    HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France - January 1997 to December 2006.
    Ndiaye B; Ould-Kaci K; Salleron J; Bataille P; Bonnevie F; Choisy P; Cochonat K; Fontier C; Guerroumi H; Ajana F; Chaud P; Yazdanpanah Y
    Antivir Ther; 2009; 14(4):567-75. PubMed ID: 19578242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
    AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency.
    Micheloud D; Berenguer J; Bellón JM; Miralles P; Cosin J; de Quiros JC; Conde MS; Muñoz-Fernández MA; Resino S
    J Infect; 2008 Feb; 56(2):130-6. PubMed ID: 18192020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.